SEQURE DX

Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic... Our state-of-the-art gene editing off-target identification technology is a versatile first-in-class diagnostic platform which will bring confidence in these life-saving gene editing treatments to patients, therapeutics developers, and regulatory agencies.

Also known as: SeQure Dx, Inc.

Primary location: Waltham United States